晚期胃癌化疗联合过继免疫细胞治疗对生命质量的影响及疗效

Effect of immunocal cells combined with chemotherapy on life quality of patients with advanced gastric cancer

目的研究化疗联合DC-CIK免疫细胞治疗对晚期胃癌患者生命质量的影响及其疗效。方法选取180例诊断为晚期胃癌的患者根据来诊时间排序,序列号为单号患者作为观察组,序列号双号患者作为对照组,每组90例。两组患者均给予常规化疗(奥沙利铂+5-氟尿嘧啶)治疗,观察组在常规化疗的基础上行DC-CIK免疫细胞治疗,治疗前后用"肿瘤生命质量核心问卷(QLQ-C30)"进行评估并比较两组患者的生命质量,观察并记录治疗过程中的不良反应并评估两组患者近期临床疗效。结果治疗前,两组之间差异无统计学意义,治疗后,观察组的QLQ-C30问卷中整体功能、特异性症状模块各个指标及整体生命质量评分显著高于对照组(P<0.05),疲劳、恶心呕吐、疼痛、气促、睡眠障碍、食欲差等特异性指标显著低于对照组(P<0.05);两组患者治疗后均出现不同程度骨髓抑制,但观察组发生率低于对照组(P<0.05)。结论 DC-CIK联合常规化疗能改善晚期胃癌患者的生命质量且不良反应较小。

Objective To study the clinical effect of DC-CIK combined with chemotherapy on quality of life of patients with advanced gastric cancer. Methods One hundred and eighty cases diagnosed with advanced gastric cancer were randomly divided into observation group （90 cases） and control group （ 90 cases）. Both groups of patients were treated with chemotherapy （ oxaliplatin ＋ 5-fluorouracil）, but observation group additionally received DC-CIK treatment. Core quality of life questionnaires （QLQ-C30） were used to compare the quality of life of these patients before and after treatment, adverse reactions were recorded, and the clinical efficacy was assessed. Results After treatment, the short-term clinical efficacy in observation group was better than in control group, but there was no statistically significant difference （ P 〉 0.05 ）. After treatment, the scores of allomeric function and symptom specific modules in QLQ-C30 became lower in control group （ P 〈 0.05 ） , but became better in observation group （ P 〈 0.05 ）. Fever, chills combined with fever, rash appeared in the two groups but there was no statistically significant difference （ P 〉 0.05 ）. After treatment, arrest of bone marrow occurred in the two groups, and the incidence was lower in observation group than in control group （ P 〈 0.05 ）. Conclusions Chemotherapy combined with DC-CIK can improve the quality of life of patients with advanced gastric cancer with fewer adverse reactions.